Saladax is a personalized medicine diagnostics company that has developed immunoassay technology for dose management of chemotherapy agents. Saladax assays are evidence-based tools that help guide the clinician in providing effective and safe drug therapy to individual patients. Most cancer drugs have a narrow therapeutic index and a dose limiting toxicity profile that make these drugs ideal candidates for dose management through the measurement of drug concentrations in blood. These simple blood tests enable an oncologist to optimize dosing for target drug levels to achieve optimal balance of efficacy and toxicity, where the loss of this balance can have devastating effects on patients.
Saladax is developing a portfolio of assays for the most common anticancer drugs, with 5-fluorouracil being the first to become available to the oncology community.
The Company aggressively protects its intellectual property with patents. Presently, these applications cover 90% of the identified market opportunity. Seven patents have been issued as of April 2009 and seven others are pending. The Company's new product pipeline consists of twelve oncology drug assays and three Central Nervous System (CNS) disorder drug management assays.
Saladax Biomedical, Inc., founded in early 2004, is headquartered at Ben Franklin TechVentures on the campus of Lehigh University in Bethlehem, Pennsylvania. A European subsidiary is located in Basel, Switzerland.